CK1 Inhibitor Program
Resistant Acute Myeloid Leukemia (AML), Solid Tumors (PDAC, TNBC, Melanoma, Prostate Cancer)
PreclinicalActive
Key Facts
Indication
Resistant Acute Myeloid Leukemia (AML), Solid Tumors (PDAC, TNBC, Melanoma, Prostate Cancer)
Phase
Preclinical
Status
Active
Company
About CasInvent Pharma
CasInvent Pharma is a private, preclinical-stage biotech leveraging a proprietary platform of best-in-class CK1 kinase inhibitors to address therapy-resistant cancers. Founded as a university spin-off with backing from i&i Prague, the company is advancing a lead candidate towards clinical trials for AML and solid tumors such as pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC). The leadership team combines deep drug discovery expertise from Big Pharma with strong academic roots in CK1 biology and chemistry, positioning the company to potentially unlock a novel oncology target.
View full company profile